MOLECULAR PHARMACOLOGY (USA) LTD. (MLPH) financial statements (2021 and earlier)

Company profile

Business Address DRUG DISCOVERY RESEARCH CENTRE
PERTH, WESTERN AUSTRALIA, 00000
State of Incorp. NV
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

6/30/2014
6/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27
Cash and cash equivalents27
Receivables65
Other undisclosed current assets00
Total current assets:912
Noncurrent Assets
Property, plant and equipment00
Total noncurrent assets:00
TOTAL ASSETS:912
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3522
Accounts payable3522
Total current liabilities:3522
Noncurrent Liabilities
Other undisclosed liabilities2,2072,045
Total liabilities:2,2422,066
Stockholders' equity
Stockholders' equity attributable to parent, including:(2,233)(2,054)
Common stock112112
Additional paid in capital107107
Accumulated deficit(2,179)(2,062)
Other undisclosed stockholders' equity attributable to parent(272)(210)
Total stockholders' equity:(2,233)(2,054)
TOTAL LIABILITIES AND EQUITY:912

Income statement (P&L) ($ in thousands)

6/30/2014
6/30/2013
Operating expenses(7)(1)
Other undisclosed operating loss(110)(208)
Operating loss:(117)(209)
Net loss:(117)(209)
Other undisclosed net loss attributable to parent (1)
Net loss available to common stockholders, diluted:(117)(210)

Comprehensive Income ($ in thousands)

6/30/2014
6/30/2013
Net loss:(117)(209)
Comprehensive loss:(117)(209)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(62)235
Comprehensive income (loss), net of tax, attributable to parent:(179)26

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: